Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.35 |
| ▸ | CTSS | P25774 | 9/20 | 0.35 |
| ▸ | CTSK | P43235 | 9/20 | 0.35 |
| ▸ | CTSB | P07858 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PTPRB | P23467 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL739506 | 0.76 | MAPK1 (0.44) | CTSLMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL738792 | 0.72 | ALDH1A1 (0.37) | MEN1ALDH1A1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL7865687 | 0.69 | CTSK (0.42) | CTSLCTSSCTSKCTSBALDH1A1 | |
| SCHEMBL583634 | 0.69 | KMT2A (0.38) | CTSLMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL16075830 | 0.69 | ALDH1A1 (0.39) | MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL21413194 | 0.68 | MEN1 (0.43) | CTSSCTSKMEN1ALDH1A1TSHR | |
| SCHEMBL19601333 | 0.67 | ALDH1A1 (0.37) | MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1351011 | 0.67 | LATS1 (0.37) | CTSLMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL5111928 | 0.67 | KMT2A (0.36) | CTSLMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL23319142 | 0.67 | MEN1 (0.33) | CTSLMEN1ALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2870140-B1 | TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | LUPIN LTD (IN) | 2016-07-27 | — | — | EP | disclosed |
| US-9359367-B2 | Tetrahydroquinazolinone derivatives as PARP inhibitors | LUPIN LIMITED (IN) | 2016-06-07 | — | — | US | disclosed |
| US-20150152118-A1 | Tetrahydroquinazolinone Derivatives as PARP Inhibitors | LUPIN LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
| EP-2870140-A1 | TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | Lupin Limited (IN) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014009872-A1 | TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | LUPIN LIMITED (IN) | 2014-01-16 | — | — | WO | disclosed |
| US-8378119-B2 | Method for producing asymmetric tetrasubstituted carbon atom-containing compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20120172605-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-8138352-B2 | Method for producing asymmetric tetrasubstituted carbon atom-containing compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20110144339-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-06-16 | — | — | US | disclosed |
| US-7928232-B2 | Method for producing asymmetric tetrasubstituted carbon atom-containing compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
| US-20090054648-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1882685-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-01-30 | — | — | EP | disclosed |
| EP-1656354-B1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-7223767-B2 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1656354-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050038052-A1 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC | 2005-02-17 | — | — | US | disclosed |
| WO-2005014557-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-5132463-A | Cardiovascular, skin, kidney, respiratory system, and gastrointestinal disorders | MERCK & CO., INC. (US) | 1992-07-21 | — | — | US | disclosed |
| US-5047420-A | Platelet activating factor | MERCK & CO., INC. (US) | 1991-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172605-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DHPS, COASY, NQO2 | CTSL 2158/4885CTSS 1117/4885CTSK 2120/4885 |
| US-20110144339-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | ACSL3, NQO2, COASY | CTSL 1283/4885CTSS 2526/4885CTSK 1097/4885 |
| US-20090054648-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | ACSL3, ARL1, NQO2 | CTSL 599/4885CTSS 2521/4885CTSK 991/4885 |
| US-20050038052-A1 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | CRHR1, AVPR2, CRHR2 | CTSL 1388/4885CTSS 963/4885CTSK 862/4885 |
| US-20150152118-A1 | Tetrahydroquinazolinone Derivatives as PARP Inhibitors | PARP1, PARP11, PARP3 | CTSL 2327/4885CTSS 2848/4885CTSK 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.